The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Vascular endothelial growth factor (VEGF)-D and clinical outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with second-line FOLFIRI plus bevacizumab (Bev): A biomarker study of the WJOG 6210G trial.
 
Naoki Izawa
Consulting or Advisory Role - Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono; MSD; MSD; MSD; MSD; Sanofi; Sanofi; Sanofi; Sanofi; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
 
Kohei Shitara
Honoraria - Abbvie; Abbvie; Abbvie; Abbvie; Novartis; Novartis; Novartis; Novartis; Yakult Pharmaceutical; Yakult Pharmaceutical; Yakult Pharmaceutical; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Lilly; Lilly; Lilly; Lilly; MSD; MSD; MSD; MSD; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Pfizer; Pfizer; Pfizer; Pfizer; Takeda; Takeda; Takeda; Takeda
Research Funding - Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Mediscience Planning (Inst); Mediscience Planning (Inst); Mediscience Planning (Inst); Mediscience Planning (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Toshiki Masuishi
Honoraria - Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Sanofi; Sanofi; Sanofi; Sanofi; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda; Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha
Research Funding - Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha
 
Tadamichi Denda
Speakers' Bureau - Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst); Yakult Honsha (Inst); Yakult Honsha (Inst); Yakult Honsha (Inst)
Research Funding - MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst)
 
Kentaro Yamazaki
Honoraria - Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono; MSD; MSD; MSD; MSD; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Sanofi; Sanofi; Sanofi; Sanofi; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda; Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha
Research Funding - Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Toshikazu Moriwaki
Speakers' Bureau - Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Lilly Japan; Lilly Japan; Lilly Japan; Lilly Japan; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Sanofi; Sanofi; Sanofi; Sanofi; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda; Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha
Research Funding - Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Yakult Honsha (Inst); Yakult Honsha (Inst); Yakult Honsha (Inst); Yakult Honsha (Inst)
 
Hiroyuki Okuda
No Relationships to Disclose
 
Chihiro Kondoh
No Relationships to Disclose
 
Tomohiro Nishina
Honoraria - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Nihonkayaku; Nihonkayaku; Nihonkayaku; Nihonkayaku; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda
Research Funding - Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Lilly Japan (Inst); Lilly Japan (Inst); Lilly Japan (Inst); Lilly Japan (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Akitaka Makiyama
Speakers' Bureau - Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Lilly; Lilly; Lilly; Lilly; Takeda; Takeda; Takeda; Takeda
 
Hideo Baba
Honoraria - Lilly; Lilly; Lilly; Lilly
Research Funding - Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); MSD K.K (Inst); MSD K.K (Inst); MSD K.K (Inst); MSD K.K (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Shin Nippon Biomedical (Inst); Shin Nippon Biomedical (Inst); Shin Nippon Biomedical (Inst); Shin Nippon Biomedical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst); Yakult Honsha (Inst); Yakult Honsha (Inst); Yakult Honsha (Inst)
 
Hironori Yamaguchi
No Relationships to Disclose
 
Masato Nakamura
Honoraria - Bayer; Bayer; Bayer; Bayer; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda; Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha
 
Yu Sunakawa
Honoraria - Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Lilly Japan; Lilly Japan; Lilly Japan; Lilly Japan; Merck; Merck; Merck; Merck; Nippon Kayaku; Nippon Kayaku; Nippon Kayaku; Nippon Kayaku; Sanofi; Sanofi; Sanofi; Sanofi; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda; Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha
Consulting or Advisory Role - Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Takeda; Takeda; Takeda; Takeda
Research Funding - Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); Lilly Japan (Inst); Lilly Japan (Inst); Lilly Japan (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Kohei Akiyoshi
No Relationships to Disclose
 
Mikio Sato
No Relationships to Disclose
 
Kimio Yonesaka
Speakers' Bureau - Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo
Patents, Royalties, Other Intellectual Property - Patents pending joint application with Daiichi-Sankyo; Patents pending joint application with Daiichi-Sankyo; Patents pending joint application with Daiichi-Sankyo; Patents pending joint application with Daiichi-Sankyo
 
Takayuki Yoshino
Research Funding - Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); PAREXEL International Inc. (Inst); PAREXEL International Inc. (Inst); PAREXEL International Inc. (Inst); PAREXEL International Inc. (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Sumitomo Dainippon (Inst); Sumitomo Dainippon (Inst); Sumitomo Dainippon (Inst)
 
Takeharu Yamanaka
Employment - Merck (I); Merck (I); Merck (I); Merck (I)
Honoraria - Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda
Consulting or Advisory Role - Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; HUYA Bioscience International; HUYA Bioscience International; HUYA Bioscience International; HUYA Bioscience International; Sysmex; Sysmex; Sysmex; Sysmex
Research Funding - Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Chugai/Roche (Inst); Chugai/Roche (Inst); Chugai/Roche (Inst); Chugai/Roche (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Kei Muro
Honoraria - Bayer; Bayer; Bayer; Bayer; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Sanofi; Sanofi; Sanofi; Sanofi; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda; Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha
Research Funding - Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Kyowa Hakko Kirin (Inst); Kyowa Hakko Kirin (Inst); Kyowa Hakko Kirin (Inst); Kyowa Hakko Kirin (Inst); Mediscience Planning (Inst); Mediscience Planning (Inst); Mediscience Planning (Inst); Mediscience Planning (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Parexel International (Inst); Parexel International (Inst); Parexel International (Inst); Parexel International (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Shionogi (Inst); Shionogi (Inst); Shionogi (Inst); Shionogi (Inst); Solasia Pharma (Inst); Solasia Pharma (Inst); Solasia Pharma (Inst); Solasia Pharma (Inst); Sumitomo Dainippon (Inst); Sumitomo Dainippon (Inst); Sumitomo Dainippon (Inst); Sumitomo Dainippon (Inst)